Phyllis Arthur's Testimony to Senate HELP Committee on Lessons Learned from Covid-19
July 27, 2021
COVID-19 will not be our last public health emergency. We face numerous bio-threats from natural and bioterror threats. Strong support for medical countermeasures R&D is critical to protecting our national security.
Today I will share BIO’s thoughts on how to strengthen our national preparedness through coordinated leadership, expanded partnership with industry and better public health infrastructure.
On behalf of its member organizations, Biotechnology Innovation Organization (“BIO”) respectfully submits this Comment in response to the United States Patent and Trademark Office’s (the “Patent Office” or “PTO”) February 13, 2024 Request for…
BIO submits comments on the MDH’s proposed regulations regarding Drugs of Substantial Public Interest: Draft Methodology for Public Comment as required in statute by the Prescription Drug Price Transparency Act.
COVID-19 will not be our last public health emergency. We face numerous bio-threats from natural and bioterror threats. Strong support for medical countermeasures R&D is critical to protecting our national security.
Today I will share BIO’s thoughts on how to strengthen our national preparedness through coordinated leadership, expanded partnership with industry and better public health infrastructure.